Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant

This article was originally published in The Pink Sheet Daily

Executive Summary

Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.

You may also be interested in...



Has Aldea Hit On A Sober Approach To Alcohol-Intoxication Therapy?

Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.

Bioavailability Key In Naloxone Studies, FDA Official Says

FDA provides a “road map” for potential sponsors of nonclinical and clinical trials of the opioid overdose treatment.

Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?

Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.

Related Content

Topics

UsernamePublicRestriction

Register

PS072646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel